Get the Stockscreener App
7.15
2.46%
-0.18
Eyepoint Pharmaceuticals Inc stock is traded at $7.15, with a volume of 87,542.
It is down -2.46% in the last 24 hours and up +13.31% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$7.33
Open:
$7.36
24h Volume:
87,542
Relative Volume:
0.11
Market Cap:
$501.72M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-3.9286
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
+4.84%
1M Performance:
+13.31%
6M Performance:
-21.43%
1Y Performance:
-67.63%
1-Day Range:
$7.145
$7.58
1-Week Range:
$6.7125
$7.61
52-Week Range:
$5.67
$23.97
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
7.15 | 501.72M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.81 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.98 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.98 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.67 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.16 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
EyePoint Pharmaceuticals at Leerink’s Conference: DuraView’s Promising Potential By Investing.com - Investing.com Canada
Research Analysts Set Expectations for EYPT FY2025 Earnings - Defense World
Q1 EPS Estimate for EyePoint Pharmaceuticals Cut by Analyst - Defense World
EyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2023 Financial Re - GuruFocus.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Full-Year Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Rhumbline Advisers Purchases 12,443 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Chardan Capital Reiterates “Buy” Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews - Benzinga
EyePoint Pharmaceuticals: Promising Clinical Progress and Strong Financial Position Justify Buy Rating - TipRanks
H.C. Wainwright maintains EyePoint stock Buy rating, $22 target - Investing.com India
H.C. Wainwright maintains EyePoint stock Buy rating, $22 target By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Call Transcript - Insider Monkey
Despite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32k - Yahoo Finance
EyePoint Pharmaceuticals: Q4 Earnings Snapshot - Midland Daily News
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highli - GuruFocus.com
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... - Yahoo Finance
EyePoint Pharmaceuticals Reports 2024 Financial Results - TipRanks
EyePoint Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Earnings call transcript: EyePoint Pharmaceuticals Q4 2024 results show revenue beat, EPS miss - Investing.com India
Earnings call transcript: EyePoint Pharmaceuticals Q4 2024 results show revenue beat, EPS miss By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
EyePoint Pharmaceuticals Q4 2024 Earnings: Revenue Beats at $11. - GuruFocus.com
EYEPOINT PHARMACEUTICALS Earnings Results: $EYPT Reports Quarterly Earnings - Nasdaq
EyePoint Pharmaceuticals shares jump nearly 5% on revenue beat By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals shares jump nearly 5% on revenue beat - Investing.com
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments - The Manila Times
EyePoint Pharmaceuticals, Inc. Q4 Loss Increases, Misses Estimates - Nasdaq
EyePoint Reports Mixed Earnings: Can Its $371M War Chest and Promising Eye Disease Pipeline Deliver Returns? - StockTitan
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result - Yahoo Finance
Eyepoint Announces Participation At Upcoming Investor Conferences - MENAFN.COM
EyePoint Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Nasdaq
How to Watch EyePoint's March Presentations at Two Major Healthcare Investment Conferences - StockTitan
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Buy” from Brokerages - Defense World
EyePoint Pharmaceuticals (EYPT) Projected to Post Earnings on Wednesday - MarketBeat
(EYPT) Technical Pivots with Risk Controls - Stock Traders Daily
EyePoint Pharmaceuticals (EYPT) Projected to Post Quarterly Earnings on Thursday - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) May Have Run Too Fast Too Soon With Recent 30% Price Plummet - Simply Wall St
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025 - The Manila Times
When Will EyePoint Reveal Its 2024 Performance? Key Date for Retinal Disease Innovator - StockTitan
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference - The Manila Times
Will EyePoint's New Clinical Data Reveal Breakthrough in Macular Degeneration Treatment? - StockTitan
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 13.6%Still a Buy? - MarketBeat
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates - MSN
Adversity is less terrifying than hope: EyePoint Pharmaceuticals Inc (EYPT) - SETE News
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Grants Stock Options to New Employees as Inducement Awards - Nasdaq
EyePoint Grants Strategic Stock Options Worth $136,500 to Key New Hires - StockTitan
(EYPT) Trading Advice - Stock Traders Daily
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eyepoint Pharmaceuticals Inc Stock (EYPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lurker Nancy | Director |
Feb 09 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
205,436 |
| Duker Jay S. | President and CEO |
Feb 09 '25 |
Option Exercise |
0.00 |
7,000 |
0 |
79,706 |
| Elston George | Chief Financial Officer |
Jan 06 '25 |
Option Exercise |
0.00 |
15,285 |
0 |
73,374 |
| Elston George | Chief Financial Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
15,000 |
0 |
63,356 |
| Lurker Nancy | Director |
Jan 06 '25 |
Option Exercise |
0.00 |
75,134 |
0 |
185,436 |
| Lurker Nancy | Director |
Jan 05 '25 |
Option Exercise |
0.00 |
12,667 |
0 |
110,302 |
| Landis John B. | Director |
Jan 05 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
21,400 |
| Duker Jay S. | President and CEO |
Jan 06 '25 |
Option Exercise |
0.00 |
20,794 |
0 |
78,814 |
| Duker Jay S. | President and CEO |
Jan 05 '25 |
Option Exercise |
0.00 |
30,000 |
0 |
68,027 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):